Clinical trial to evaluate on the efficacy of Ayurvedic intervention in Vidangadi Lauha and Trayushanadi Lauha with Phalatrikadi Kwath in MEDOROGA (DYSLIPIDEMIA)

A Randomized Comparative Clinical Study To Evaluate The Efficacy Of Vidangadi Lauha And Trayushanadi Lauha With Phalatrikadi Kwath In Medoroga (Dyslipidemia) - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/101004

Enrollment

Registered

2026-01-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E782- Mixed hyperlipidemia

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: i)Adults in the age group of 18 to 60 years of either sex. ii)LDLC more than and equal to 130 mg/dl and less than and equal to 190 mg/dl. iii)Cholesterol more than and equal to 200 mg/dl and less than and equal to 300mg/dl. iv)Triglycerides level more than and equal to 150 mg/dl and less than and equal to 300mg/dl. v)Those who have voluntarily signed the written informed consent. If any one of the following criteria is met patient will be included .

Exclusion criteria

Exclusion criteria: i)Patients having history of angina, Myocardial infarction and cerebrovascular accidents. ii)Patients having Systolic blood pressure (SBP) & Diastolic blood pressure (DBP) more than an equal to 160 &100 mm of Hg respectively. iii)Patients with uncontrolled diabetes mellitus with FBS level more than 160 mg/dl or HbA1c higher than 8%. iv)Patients having hypothyroidism with TSH level more than and equal to 1.5 times the upper limit of normal. v)Patients having statins, fibric acid derivatives, cholestyramine, nicotinic acid, proprotein convertase subtilisin/kexin type 9 inhibitors, corticosteroids, diuretics, amiodarone, cyclosporine. vi)Patients with chronic disorders like Nephrotic syndrome, Renal failure, Auto immune disorders, Chronic Liver Disease (AST or ALT levels more than 2 times the upper limit of normal), and other serious diseases (vii)Pregnant women and lactating mother and females of child bearing age willing to conceive during trial period.

Design outcomes

Primary

Measure	Time frame
The primary outcome of the study will be the change in LDL-C levels from baseline to the end of the treatment period.Timepoint: baseline to the end of the treatment period.	—

Secondary

Measure	Time frame
Changes in Blood levels of TC, HDL-C, TG, fasting blood glucose, TC:HDL-C, SGOT, SGPT, S.Creatinine.Timepoint: baseline to the end of the treatment period.	—

Countries

India

Contacts

Public ContactDR HARI MOHAN LAL MEENA

National Institute of Ayurveda, Deemed to be university, Jaipur

hari_mohan68@yahoo.co.in9461297017

Outcome results